VolitionRx Limited announced that it has closed its first commercial transaction of its Nu.Q® Cancer assays, delivering the platform to Hospices Civils de Lyon, a leading cancer treatment and research institution in France. The sale marks the company’s first revenue‑generating event in the human oncology market and signals early traction for the Nu.Q® platform, which measures methylated nucleosome biomarkers to aid clinicians in treatment decisions and patient monitoring.
While the announcement does not disclose the financial value or volume of assays sold, the transaction is a critical validation of the technology’s clinical utility. It also demonstrates VolitionRx’s ability to secure a high‑profile customer, a prerequisite for scaling the platform across additional European centers and for pursuing broader licensing and distribution agreements.
The sale comes on the heels of VolitionRx’s Q3 2025 financial results, in which the company reported $0.6 million in revenue—up 32% year‑over‑year—against a net loss of $0.05 per share. Operating expenses fell 10% YoY, and net cash used in operations dropped 33% to $3.6 million. The company’s revenue shortfall relative to the $1.98 million forecast underscores the need for additional sales volume and licensing deals to reach its 2025 cash‑neutrality target.
VolitionRx’s strategy to commercialize the Nu.Q® platform includes partnerships with Werfen and Hologic, which broaden market reach and provide alternative revenue streams. The first sale to Hospices Civils de Lyon strengthens the company’s commercial pipeline and supports its goal of achieving cash‑neutral operations by the end of 2025, even as it continues to invest in product development and regulatory approvals.
President and Group CEO Cameron Reynolds emphasized that the transaction “confirms the clinical value of the Nu.Q® platform and provides a foundation for expanding our presence in the human diagnostics market.” He added that the company remains focused on scaling the platform through strategic licensing agreements and that the first sale is a milestone toward broader adoption across oncology practices.
Investors have approached the announcement with measured caution, noting that while the sale validates the technology, the company’s broader financial performance remains modest and the revenue contribution from this single transaction is not yet material to the overall top line. Nonetheless, the transaction is viewed as a positive step toward the company’s commercialization roadmap and its cash‑neutrality objective.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.